Lishengpharma(SZ:002393)2026-03-09 10:15Revenue and Profit - The total operating revenue for 2025 reached ¥1,392,663,934.63, an increase of 4.23% compared to the previous year[5] - The total profit for 2025 was ¥456,432,176.66, reflecting a significant increase of 111.36% year-over-year, driven by market expansion and increased product sales[5] - The net profit attributable to shareholders of the listed company was ¥418,365,973.76, up 126.72% from the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥169,084,905.34, which is a 64.16% increase year-over-year[5] - Basic earnings per share increased to ¥1.62, representing a growth of 125.00% compared to the previous year[4] Financial Ratios and Returns - The weighted average return on net assets rose to 8.56%, an increase of 4.82 percentage points from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were ¥5,584,429,772.98, a decrease of 3.48% from the beginning of the period[4] - The equity attributable to shareholders of the listed company decreased to ¥4,630,138,992.15, down 2.93% from the beginning of the period[4] - The net asset per share attributable to shareholders was ¥17.98, a decrease of 2.81% compared to the previous period[4] Financial Data Confirmation - The company confirmed that the disclosed financial data is within the previously announced performance forecast range, indicating no discrepancies[7]